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ABSTRACT
Background: The benefits of direct stenting in non-ST-segment-
elevation acute coronary syndromes (NSTE ACS) are not 
clearly established. We compared stenting with or without 
pre-dilation (direct stenting) of the target lesion in this popula-
tion. Methods: Single center, retrospective registry including 
NSTE ACS patients treated from 2009 to 2010. Stenting for 
bifurcations, saphenous vein grafts, and in-stent restenosis 
were excluded. The primary endpoint was the comparison 
of in-hospital and late major adverse cardiac events (MACE). 
Results: Of a total of 182 patients, 42.3% were treated by 
direct stenting. Mean age was 61.1 ± 11.0 years, 67% were 
male and 33.5% were diabetics. Patients in the pre-dilation 
group had more type C lesions (37.1% vs. 18.2%; P = 0.01), 
smaller reference vessel diameter (2.3 [2.0-2.7] mm vs. 2.7 
[2.2-3.1] mm; P = 0.01) and smaller preintervention minimal 
luminal diameter (0.5 [0.1-0.7] mm vs.0.6 [0.4-1.0] mm; P < 
0.01). Moderate/severe calcification was observed in 13.2% 
of the cases, and was equally distributed in both groups. 
There were no differences in the occurrence of periprocedural 
angiographic complications (3.9% vs. 4.8%; P = 0.99). In-
hospital MACE was not different between groups, although 
patients submitted to direct stenting have shown half of the 
events (2.6% vs. 5.7%; P = 0.47). At the end of 1 year, the 
MACE rate was similar for the two groups (6.5% vs. 5.7%; 
P > 0.99). Conclusions: In this series of NSTE ACS patients, 
direct stenting was not associa ted with better angiographic 
or clinical outcomes. However, lesion complexity remains a 
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RESUMO
Implante de Stents Com ou Sem Pré-Dilatação em 
Pacientes com Síndrome Coronária Aguda Sem 
Supradesnivelamento do Segmento ST
Introdução: O benefício do implante direto de stent não está bem 
estabelecido na síndrome coronária aguda sem supradesnivela-
mento do segmento ST (SCASST). Comparamos aqui o implante 
de stent, como usem pré-dilatação (stent direto) da lesão-alvo 
nessa população. Métodos: Registro unicêntrico, retrospectivo, 
que incluiu pacientes com SCASST tratados entre 2009 a 2010. 
Foram excluídas lesões reestenóticas, lesões em enxertos de safena 
ou em bifurcações. O desfecho primário foi a comparação de 
eventos cardíacos adversos maiores (ECAM) hospitalares e tardios. 
Resultados: Do total de 182 pacientes avaliados, 42,3% foram 
tratados com stent direto. A idade da população foi de 61,1 ± 
11,0 anos, sendo 67% do sexo masculino e 33,5% diabéticos. 
Os pacientes do grupo pré-dilatação apresentaram mais lesões 
do tipo C (37,1% vs. 18,2%; P < 0,01), menor diâmetro de 
referência do vaso (2,3 [2,0-2,7] mm vs. 2,7 [2,2-3,1] mm; P 
< 0,01) e menor diâmetro luminal mínimo pré-intervenção (0,5 
[0,1-0,7] mm vs. 0,6 [0,4-1,0] mm; P < 0,01). Calcificação 
moderada/grave foi evidenciada em 13,2% dos casos, igualmente 
distribuídos entre os grupos. Não foram observadas diferenças 
na ocorrência de complicações angiográficas periprocedimento 
(3,9% vs. 4,8%; P > 0,99). As taxas de ECAM hospitalar não 
diferiram entre os grupos, embora os pacientes submetidos ao 
implante direto tenham apresentado metade dos eventos (2,6% 
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determinant factor in the choice of the pre-dilation strategy 
in daily practice.
 
 
 
 
 
DESCRIPTORS: Acute coronary syndrome. Percutaneous co-
ronary intervention. Stents.
Percutaneous coronary intervention 
Previously, all patients had received acetylsalicylic acid 
(loading dose of 300 mg and maintenance with 100 mg/day), 
clopidogrel (loading dose of 300/600 mg and 75 mg for 
maintance/day), and low molecular weight heparin (1 mg/kg 
every 12 hours). The use of glycoprotein IIb/IIIa as an adju-
vant to the procedure was at the discretion of the operator.
Percutaneous coronary intervention was performed 
via femoral or radial approach, as decided by the 
operator. All procedures were performed according to 
the recommendations of the current guidelines.9 Dur-
ing the intervention, unfractionated heparin (UFH) was 
administered at a dose of 70 to 100 IU/kg in patients 
who had not received low molecular weight heparin 
(LMWH) 12 hours before the procedure.
The choice of implant technique (i.e. pre-dilation 
or direct stenting) was at the discretion of the operator. 
After the procedure, patients continued to receive dual 
antiplatelet therapy with acetylsalicylic acid 100 mg/
day indefinitely and clopidogrel 75 mg/day for at least 
one month in case of bare-metal stents, and for one 
year if the device was a drug-eluting stent.
Qualitative and quantitative coronary 
angiography
Quantitative coronary angiography (QCA) was obtained 
in multiple projections and similar incidences before 
and after stenting. The QCA offline analysis included the 
measurement of the following parameters: vessel reference 
diameter, minimal luminal diameter, lesion length, pre- and 
postprocedural percentage of stenosis diameter (reference 
diameter – minimum lumen diameter/reference diameter × 
100), and acute gain. The lesions were classified accord-
ing to the American Heart Association/American College 
of Cardiology criteria. The morphological characteristics 
of the lesion (eccentricity, tortuosity, angulation > 45°, 
thrombus, occlusion, calcification, etc.) were evaluated. 
The degree of antegrade blood flow was measured in ac-
cordance with the Thrombolysis in Myocardial Infarction 
(TIMI) classification.
Primary outcome
The primary goal of this study was to compare 
the clinical outcomes, with inclusion of periprocedural 
vs. 5,7%; P = 0,47). Ao final de 1 ano, os ECAM foram seme-
lhantes entre os grupos (6,5% vs. 5,7%; P > 0,99 ). Conclusões: 
Nesta série de pacientes com SCASST, o implante direto de stent 
não esteve associado a melhores resultados angiográficos ou 
clínicos. Contudo, a complexidade da lesão permanece como 
fator determinante na escolha da estratégia de pré-dilatação na 
prática diária.
DESCRITORES: Síndrome coronariana aguda. Intervenção 
coronária percutânea. Stents.
P revious trials have demonstrated that the technique of direct stenting is superior to pre-dilation with balloon catheter, regarding the reduction in the 
occurrence of disorders in coronary flow during the 
procedure (slow flow/no-reflow), resulting in a lower 
incidence of periprocedural myocardial infarction, par-
ticularly in patients with acute coronary syndrome (ACS), 
with or without ST-segment elevation.1 Other potential 
advantages of this technique include less time of ex-
posure to radiation, a reduction in the duration of the 
procedure, the use of less constrast, and lower costs.2-8
However, a major limitation of the direct im-
plantation relates to the capacity of stents of cross-
ing lesions that are often severe and complex (e.g. 
with tortuosity and calcification). With the advent 
of new, thinner, and more flexible metal platforms 
and the use of new metal alloys (cobalt-chromium, 
platinum-chromium, among others), it has become 
easier to perform direct stenting.
The present analysis aims to compare the imme-
diate outcomes and those at one year of a cohort of 
patients with non-ST-segment elevation acute coronary 
syndrome (NSTE-ACS) treated with stenting, with or 
without pre-dilation (direct stenting) of the target lesion.
METHODS
Study design and population evaluated
This was a single-center, retrospective, and nonran-
domized registry, which included patients with NSTE-ACS 
undergoing percutaneous coronary intervention, divided 
according to stent implantation strategy (pre-dilation 
vs. direct stenting).
This study included patients with a single de novo 
lesion in native coronary arteries. Patients with restenotic 
lesions, lesions located in vein grafts, true bifurcation 
lesions (lateral branches > 2.0 mm and with > 50% 
stenosis), with lesion in the left main coronary artery, 
and patients who did not return for follow-up at this 
institution were excluded. 
The trial protocol was approved by the Research 
Ethics Committee of this institution, and all patients 
signed an informed consent for the performance of the 
percutaneous coronary intervention.
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angiographic complications (flux disturbance: slow 
flow/no-reflow, thrombus, and occlusion of lateral 
branch) and major adverse cardiac events (MACE), 
such as tar get-vessel revascularization, acute myocar-
dial infarction, and death, that occurred in hospital 
and within one year.
Definitions
NSTE-ACS was defined as a typical chest pain at 
rest or with minimal exertion, with or without T-wave 
inversion and/or ST-segment depression > 0.5 mm in 
the electrocardiogram, with or without elevation of 
serum markers of myocardial injury. 
All deaths were considered of cardiac origin un-
less another cause was identified. The diagnosis of 
periprocedural myocardial infarction was defined as 
an elevation >  3  times the normal value of CK-MB. 
Target-vessel revascularization was defined as a new 
revascularization (new percutaneous coronary interven-
tion or coronary artery bypass graft [CABG] surgery) in 
the previously treated target vessel, due to restenosis 
or disease progression. 
Angiographic success was defined as TIMI 3 distal 
flow or a residual lesion after stent implantation < 20%.
Statistical analysis
Categorical variables were expressed as absolute 
(n) and relative (%) frequency. To assess the associ ation 
between categorical variables, the chi-squared or Fisher’s 
exact test were used. Continuous variables were expressed 
as median (interquartile range). To compare groups, the 
Mann-Whitney test was used for nonparametric variables. 
P values <  0.05 were considered significant.
All analyses were performed by the Department 
of Research, Instituto Dante Pazzanese de Cardiologia, 
São Paulo, Brazil, using SPSS version 18.0.
RESULTS
From January 2009 to March 2010, 605 patients 
with NSTE-ACS were treated in this hospital, of whom 
182 (30.1%) met the trial criteria. These patients were 
divided according to the strategy used for stenting (pre-
dilation – n = 105, or direct stenting – n = 77). Figure 
1 shows the flow chart of the trial.
The clinical, angiographic, and procedural charac-
teristics are shown in Tables 1 and 2. The mean age 
was 61.1 ± 11 years, 67% were male, and 33.5% were 
diabetic. None of the clinical characteristics differed 
between the groups, except for clinical presentation, 
which showed a higher frequency of myocardial 
infarction without ST-segment elevation in the pre-
dilation group.
182 lesions were treated, and the target vessel 
more frequently addressed was the left anterior descend-
ing artery (39%). Of all lesions treated, 78.0% had a 
moderate to high degree of anatomical complexity 
(B2/C). Patients from pre-dilation group had a higher 
frequency of type-C injuries. Lesions with moderate/
severe calcification were present in 13.2% of cases, a 
feature equally distributed between groups (15.2% vs. 
10.4% P = 0.38).
198 stents (1.08 stent/patient) were used, and 2 
stents with overlapping rods needed to be implanted in 
8.7% of cases. Drug-eluting stents were used in 14.8% 
of patients who had a stent implanted, and 31.2% of 
patients had two stents implanted. In the pre-dilation 
group, the stents showed smaller diameter (3.0  mm 
[2.5-3.0] vs. 3.0 mm [3.0-3.5]; P < 0.01), and a greater 
length (18 mm [14.5 to 24.0] vs. 18 mm [12.0 to 20.0]; 
P < 0.01). The incidence of patients with distal TIMI flow 
<  3 before the procedure was higher in pre-dilatation 
group, while distal TIMI 3 flow after the procedure 
was similar between the groups (97.1% vs. 98.7%). No 
• Single injury
• De novo injury
• Single vessel
• Native vessel
605 patients with NSTE-ACS
182 patients included:
• Restenotic injury
• Injury in vascular grafts
• True bifurcation injury
• Injury in main left coronary artery
• Patients without follow-up at 1 year
423 patients excluded:
108 patients with
NSTEMI
74 patients with
unstable angina
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differences were observed between the groups in the 
occurrence of periprocedural angiographic complica-
tions: slow flow/no-reflow (2.9% vs. 3.9%; P  =  0.29), 
thrombus (1.0% vs. 1.3%; P  > 0.99), or occlusion of 
lateral branches (1.9% vs.  0; P  =  0.50).
The results of QCA are shown in Table 3. Patients 
from pre-dilation group had smaller reference vessel 
diameter (2.3 mm [2.0-2.7] vs. 2.7 mm [2.2-3.1]; P 
< 0.01) and smaller minimal lumen diameter (0.5 mm 
[0.1-0.7] vs. 0.6 mm [0.4-1.0]; P <  0.01). After stent 
implantation, the minimal luminal diameter was smaller 
in the pre-dilation group (2.2 mm [1.8-2.6] vs. 2.7 mm 
[2.3-2.9]; P < 0.01), but the acute luminal gain did not 
differ between groups (1.7 mm [1.3-2.0] vs. 1.8 mm 
[1.4-2.3]; P = 0.15). 
The incidence of MACE, although numerically greater 
in the in-hospital phase ofpatients in the pre-dilation group, 
was not statistically significant (5.7% vs. 2.6%; P = 0.47). 
At one year of follow-up, the occurrence of MACE was 
also comparable (5.7% vs. 6.5%; P > 0.99) (Table 4).
DISCUSSION
The main finding of this study was the fact that, in 
selected patients with a clinical picture of NSTE-ACS, 
direct coronary stenting is feasible without compromising 
the efficacy of the procedure. However, no angiographic 
or clinical benefit related to this strategy of stenting was 
observed, either in the immediate phase (in-hospital) or 
in the medium term (one year of clinical follow-up). 
TABLE 1 
Baseline clinical characteristics 
Characteristics
Pre-dilation  
(n = 105)
Direct 
stenting  
(n = 77) P value
Age, years 61 (53-70.5) 59 (50-68) 0.12
Male, n (%) 68 (64.8) 54 (70.1) 0.52
Hypertension, n (%) 91 (86.7) 63 (81.8) 0.41
Diabetes mellitus, n (%) 34 (32.4) 27 (35.1) 0.75
Dyslipidemia, n (%) 62 (59.0) 45 (58.4) > 0.99
Currently smoking (%) 25 (23.8) 24 (31.6) 0.30
Family history of CAD, n (%) 15 (14.3) 17 (22.1) 0.23
Prior AMI, n (%) 20 (19.0) 17 (22.1) 0.71
Prior PCI, n (%) 15 (14.3) 14 (18.4) 0.53
Previous CABG, n (%) 16 (15.2) 4 (5.2) 0.05
Clinical status, n (%) 
 STEMI 70 (66.7) 38 (49.4)
 Unstable angina 35 (33.3) 39 (50,6)
CAD = coronary artery disease; AMI = acute myocardial infarction; PCI 
= percutaneous coronary intervention; CABG = coronary artery bypass 
grafting; NSTEMI = Non-ST-segment elevation myocardial infarction. 
TABLE 2 
Angiographic and procedural characteristics
Characteristics
Pre-dilation  
(n = 105)
Direct stenting 
(n = 77) P value
Target vessel, n (%) 0.10
Left anterior descending 
circumflex 
36 (34.3) 35 (45.5)
Right coronary 40 (38.1) 18 (23.4)
Type of lesion 29 (27.6) 24 (31.2)
(AHA/ACC), n (%) 0.03
 A 1 (1.0) 3 (3.9)
 B1 19 (18.1) 18 (23.4)
 B2 47 (44.8) 42 (54.5)
 C 39 (37.1) 14 (18.2)
Lesion morphology, n (%)
 Eccentricity 72 (68.6) 52 (67.5) > 0.99
 Tortuosity 19 (18.1) 14 (18.2) > 0.99
 Angle < 45° 6 (5.7) 2 (2.6) 0.47
 Thrombus 7 (6.7) 5 (6.5) > 0.99
 Calcification 16 (15.2) 8 (10.4) 0.38
 Lateral branch involvement 19 (18.1) 8 (10.4) 0.20
 Ulcer 1 (1.0) 2 (2.6) 0.57
TIMI flow 
Pre-procedure, n (%)
0.02
 3 78 (74.3) 68 (88.3)
 < 3 27 (25.7) 9 (11.7)
TIMI flow 
post-procedure, n (%)
0.63
 3 102 (97.1) 76 (98.7)
 < 3 3 (2.9) 1 (1.3)
Stent diameter, mm 3.0 [2.5-3.0] 3.0 [3.0-3.5] < 0.01
Stent length, mm 18 [14.5-24.0] 18 [12.0-20.0] < 0.01
Drug-eluting stent, n (%) 19 (18.1) 8 (10.4) 0.20
Implantation of two stents 
with overlapping of their 
rods, n (%)
12 (11.4) 4 (5.2) 0.18
GP IIb/IIIa, n (%)  
inhibitor, n (%)
7 (6.7) 4 (5.2) 0.76
AHA/ACC = American Heart Association/American College of Cardiology; 
TIMI = Thrombolysis in Myocardial Infarction; GP = glycoprotein.
In theory, the lesions associated with SCA would 
be ideal for a direct stenting, since in over 50% of 
these patients, the culprit lesion is localized at a site 
of moderate stenosis (<  50%) by angiography.3-5,10 In 
the present population, the direct stenting procedure 
was performed in 42.3% of patients, at the discretion 
of the operator. This result is comparable with other 
international series, such as that of Süselbeck et al.,3 in 
which direct stenting was performed in 43% of patients.
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The mechanisms behind the occurrence of changes 
in coronary flow (slow flow/no-reflow) are complex and 
not yet fully understood. Mechanisms inherent to percu-
taneous coronary intervention itself, due to the effect of 
crushing and fragmentation of the atherosclerotic lesion, 
have emerged as the main cause of this phenomenon. 
The risk of microembolization during a percutaneous 
coronary intervention depends on the atherothrombotic 
load of the culprit lesion and on the degree of vascular 
aggression of the procedure. Other mechanisms described 
are: microvascular spasm, myocardial stunning, oxida-
tive stress, endothelial dysfunction, and inflammation 
and thromboxane production.11,12
Trials such as PAMI and STENTIM-2 have suggested 
a promoting effect of the no-reflow phenomenon after 
pre-dilation with balloon in patients with ACS.6,7 Like-
wise, Loubeyre et al.13 evaluated both techniques in 409 
patients with ST-segment elevation acute myocardial 
infarction (STEMI), and found a lower incidence of 
no-reflow in the group of direct stenting. Contrary to 
these results, the present study showed no significant 
difference in the incidence of coronary flow disturbance 
by both techniques of stenting. Similar results were 
obtained in the trial of Süselbecket al.,3 in which the 
incidence of no-reflow was not significantly different 
between the groups.
With regard to the impact on clinical outcomes, 
Süselbecket al.3 compared both techniques in 194 
patients with ACS (STEMI 66%, NSTEMI 18%, and 
unstable angina 16%), finding no significant differences 
between groups for in-hospital major adverse cardiac 
events (death, myocardial infarction, and CABG) (direct 
stenting 4.1% vs. pre-dilation 11.5%; P = 0.11). In the 
same line, Atmaca et al.10 evaluated the two techniques 
in a population of 145 ACS patients, and no significant 
differences were found with regard to the occurrence of 
death, AMI, or neorevascularization of the target lesion.
It is notable that the present population had greater 
complexity, representing a sample more compatible with 
the real clinical practice. This study included patients 
with lesions generally excluded from several controlled 
trials, such as calcified lesions, long stents, and those 
with overlapping.
In the past, the techniques of stenting (direct or 
pre-dilation stenting) were tested in mixed or selected 
populations, including patients with stable coronary 
artery disease, patients with NSTE-ACS and STEMI, 
or only with STEMI. This analysis represents the only 
review of a select population of NSTE-ACS (NSTEMI 
TABLE 3 
Quantitative coronary angiography
Pre-dilation (n = 105) Direct stenting (n = 77) P value
Pre-procedure 
Reference diameter, mm 2.3 [2.0-2.7] 2.7 [2.2-3.1] < 0.01
Minimal luminal diameter, mm 0.5 [0.1-0.7] 0.6 [0.4-1.0] < 0.01
Stenosis diameter,% 80.4 [73.4-95.7] 76.9 [66.9-87.4] < 0.01
Lesion length, mm 14.1 [10.0-20.7] 13.2 [10.4-17.3] 0.93
Post-procedure
Reference diameter, mm 2.7 [2.4-3.0] 2.9 [2.7-3.4] < 0.01
Minimal luminal diameter, mm 2.2 [1.8-2.6] 2.7 [2.3-2.9] < 0.01
Stenosis diameter,% 16.3 [9.9-25.4] 12.2 [8.1-19.6] < 0.01
Acute gain, mm 1.7 [1.3-2.0] 1.8 [1.4-2.3] 0.15
TABLE 4 
In-hospital clinical results and after  
one year and after one year
Pre-
dilation 
(n = 105)
Direct 
stenting 
(n = 77) P value
In-hospital results, n (%)
TVR 1 (1.0) 0 (0) > 0.99
AMI 6 (5.7) 1 (1.3) 0.24
Death 1 (1.0) 2 (2.6) 0.57
MACE 6 (5.7) 2 (2.6) 0.47
Results after one year*, n (%)
TVR 4 (3.8) 5 (6.5) 0.49
AMI 5 (4.8) 3 (3.9) > 0.99
Death 1 (1.0) 0 (0) > 0.99
MACE 6 (5.7) 5 (6.5) > 0.99
* Events not cumulative. 
TVR = target vessel revascularization; AMI = acute myocardial 
infarction; MACE = major adverse cardiac events.
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and unstable angina) with late evolution. The results of 
this trial increase the knowledge available in this field.
Limitations of the trial
This is a retrospective observational trial, with all 
the limitations inherent to this type of trial, in which 
the choice of stenting technique was left to the opera-
tor, and was based on experience. Other limitations of 
trial include the differences in angiographic baseline 
characteristics between the two groups, and the rela-
tively small number of patients analyzed in both groups.
CONCLUSIONS
In this series of patients with acute coronary syn-
drome without ST-segment elevation, the decision in 
favor of direct stenting was not associated with better 
clinical and angiographic outcomes, neither during 
hospitalization nor within one year.
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